Cargando…

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

To evaluate whether the epidermal growth factor receptor (EGFR), K-Ras and PTEN, all members of the EGFR signalling pathway, may affect the clinical response in cetuximab-treated metastatic colorectal cancer (mCRC) patients. Twenty-seven cetuximab-treated mCRC patients were evaluated for drug respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frattini, M, Saletti, P, Romagnani, E, Martin, V, Molinari, F, Ghisletta, M, Camponovo, A, Etienne, L L, Cavalli, F, Mazzucchelli, L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360431/ https://www.ncbi.nlm.nih.gov/pubmed/17940504 http://dx.doi.org/10.1038/sj.bjc.6604009

Ejemplares similares

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
por: Molinari, F, et al.
Publicado: (2009)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
por: Martin, V, et al.
Publicado: (2013)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Reply: Do we need biopsies of metastases for colorectal cancer patients?
por: Frattini, M, et al.
Publicado: (2009)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma
por: Beg, S, et al.
Publicado: (2015)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Is PTEN loss associated with clinical outcome measures in human prostate cancer?
por: McCall, P, et al.
Publicado: (2008)

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
por: Cuzick, J, et al.
Publicado: (2013)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells
por: Watanabe, T, et al.
Publicado: (2011)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
por: Yoshimoto, M, et al.
Publicado: (2007)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Mesenchymal stem cells are enriched in head neck squamous cell carcinoma, correlates with tumour size and inhibit T-cell proliferation
por: Liotta, F, et al.
Publicado: (2015)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer
por: Murata, A, et al.
Publicado: (2013)

Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer
por: Vreuls, C P H, et al.
Publicado: (2013)

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
por: Dotan, E, et al.
Publicado: (2012)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity
por: Tittarelli, A, et al.
Publicado: (2015)

Myofibroblast activation in colorectal cancer lymph node metastases
por: Yeung, T M, et al.
Publicado: (2013)

Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia
por: Malesci, A, et al.
Publicado: (2014)

MicroRNA-126 and epidermal growth factor-like domain 7–an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial
por: Hansen, T F, et al.
Publicado: (2013)

Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups
por: Mansilla, F, et al.
Publicado: (2007)

Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer
por: Andersen, C L, et al.
Publicado: (2009)

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
por: Bedognetti, D, et al.
Publicado: (2013)

Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells
por: Bose, D, et al.
Publicado: (2011)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Functions and Regulation of the PTEN Gene in Colorectal Cancer
por: Molinari, Francesca, et al.
Publicado: (2014)

Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer
por: Kim, J C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ticdscavb8ou95kmo2l5s0o68s